Bio-Techne Agrees to $11.3 Billion Acquisition by Merck KGaA

What happened

Merck KGaA entered into a definitive agreement to acquire Minnesota-based Bio-Techne Corporation for $73 per share in cash, valuing the transaction at $11.3 billion (EUR 9.9 billion). The acquisition price represents a 36% premium to Bio-Techne's one-month volume-weighted average trading price and a 24% premium on the day of announcement. The deal was announced one week after activist investor Ananym Capital Management disclosed a stake in Bio-Techne and advocated for a sale. Merck plans to fund the acquisition through a combination of cash on hand and proceeds from new debt. The transaction is subject to regulatory approvals and Bio-Techne shareholder approval, with closing expected in late 2026 or early 2027.

Why it matters

The acquisition significantly expands Merck KGaA's Life Science business by adding Bio-Techne's portfolio of over 500,000 products, including cytokines, growth factors, antibodies, immunoassay kits, and ProteinSimple automated protein detection instruments. Bio-Techne's RNAscope and in-situ hybridization technologies will enhance Merck's spatial biology and diagnostics capabilities, while its bioprocessing tools will strengthen Merck's position across the entire industry value chain-from laboratory research to biopharmaceutical manufacturing. Merck expects to realize annual cost savings of approximately 140 million euros by the third year following deal closure, which would add roughly 5% to its bottom line based on 2024 net income. For Bio-Techne, the deal provides immediate value to shareholders at a substantial premium and offers expanded geographic reach and omnichannel customer access through Merck's global infrastructure, which includes over 62,000 employees worldwide.

Bigger picture

This transaction represents Merck KGaA's largest acquisition in over a decade and signals a strategic focus on research tools and bioprocessing-a segment that tends to grow steadily regardless of individual drug lifecycles. The deal comes as research-tool companies have experienced cooling demand since the COVID-19-era boom, with labs and biopharma firms tightening budgets. Despite this backdrop, the acquisition reflects confidence in the long-term growth of advanced biotech work, particularly in cell and gene therapy, where Bio-Techne's reagents and instruments are heavily used. The healthcare sector has seen robust M&A activity, with $419 billion in deals completed in 2026 through the announcement date-the highest level since 2021. Following the announcement, Bio-Techne shares rose over 20% to approximately $71, approaching the $73 offer price, indicating strong market confidence in deal completion. Life sciences peers including Danaher and Repligen also saw stock price gains on the day.

What to watch

Investors should monitor progress toward regulatory approvals from relevant authorities and the Bio-Techne shareholder vote, both required for deal completion. The companies have indicated closing is expected in late 2026 or early 2027, so any updates on timing or conditions will be important. Additionally, watch for details on how Merck plans to integrate Bio-Techne's 3,100 employees across 34 global locations and realize the projected 140 million euro cost synergies. Any changes to the deal terms or potential competing bids, though the stock trading near the offer price suggests low expectations of a higher offer, would also be significant developments.